Calycosin attenuates diabetic vascular injury through anti‑glycation, anti‑inflammatory and endothelial metabolic effects
International Journal of Molecular Medicine · 20.11.2026 · 59 (1) · 1-14
DOI: 10.3892/ijmm.2026.6060 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Medicine, online erschienen am 20.11.2026. Verfasst von Junfeng Shi und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Advanced glycation end‑products (AGEs) contribute to diabetes‑associated endothelial injury; however, there are a limited number of therapies that target glycation‑associated inflammation and endothelial metabolic abnormalities. Calycosin is a bioactive isoflavone with anti‑inflammatory and antioxidant properties; however, its vascular protective effects in diabetes have not yet been well characterized. In the present study, AGE‑treated human umbilical vein endothelial cells (HUVECs) and mice with high‑fat diet/streptozotocin‑induced diabetes were used to investigate the effects of calycosin. Endothelial viability, apoptosis, nitric oxide (NO) release and RAGE/NF‑κB signaling were examined, and untargeted metabolomic and proteomic analyses were performed. Vascular histopathology, permeability, vasorelaxation, plasma AGE‑associated fluorescence, albumin glycation, blood glucose concentration and glucose tolerance were evaluated in vivo . Calycosin attenuated the AGE‑induced reductions in HUVEC viability and NO release, as well as the increases in apoptosis, RAGE expression and NF‑κB phosphorylation. Untargeted metabolomics identified 725 metabolites and revealed an amelioration of the AGE‑induced metabolic defects, particularly in lipid and amino acid metabolism. Proteomic analysis identified changes in the expression of RAGE‑associated signaling proteins, including protein diaphanous homolog 1 (DIAPH1), transcription factor p65 (RELA) and urokinase‑type plasminogen activator (PLAU). Pharmacological inhibition of RAGE with FPS‑ZM1 attenuated AGE‑induced NF‑κB phosphorylation. In diabetic mice, calycosin reduced the plasma AGE‑associated fluorescence and glycation of albumin, alleviated vascular remodeling and inflammation, reduced vascular permeability, and improved acetylcholine‑induced vasorelaxation. Calycosin also reduced the blood glucose concentrations and improved the glucose tolerance of the mice. Collectively, these findings indicate that calycosin attenuates diabetic vascular injury, reduces glycation and proinflammatory signaling, and modulates endothelial metabolism. These data support the potential use of calycosin as a candidate therapy for the vascular complications of diabetes.
Zitieren
APA
Shi, J., Tang, H., Chen, J., Qiu, W., Wang, Y., Zhang, W., Kan, C., Ma, Y., Qiu, H., & Sun, X. (2026). Calycosin attenuates diabetic vascular injury through anti‑glycation, anti‑inflammatory and endothelial metabolic effects. International Journal of Molecular Medicine, 59(1), 1-14. https://doi.org/10.3892/ijmm.2026.6060
Vancouver
Shi J, Tang H, Chen J, Qiu W, Wang Y, Zhang W, et al. Calycosin attenuates diabetic vascular injury through anti‑glycation, anti‑inflammatory and endothelial metabolic effects. International Journal of Molecular Medicine. 2026;59(1):1-14. doi:10.3892/ijmm.2026.6060
BibTeX
@article{Shi2026,
author = {Shi, Junfeng and Tang, Huiru and Chen, Jian and Qiu, Weixiu and Wang, Yingjie and Zhang, Wanqiu and Kan, Chengxia and Ma, Yujie and Qiu, Hongyan and Sun, Xiaodong},
title = {Calycosin attenuates diabetic vascular injury through anti‑glycation, anti‑inflammatory and endothelial metabolic effects},
journal = {International Journal of Molecular Medicine},
year = {2026},
volume = {59},
number = {1},
pages = {1--14},
doi = {10.3892/ijmm.2026.6060}
}
EUVIMED